A final study demonstrated that adding high-tech urine biomarker tests to regular cystoscopy was not cost-effective in detecting recurrences of bladder cancer. Adding the biomarker screen also increased the risk for false-positive results, the researchers found.
Cystoscopy involves looking at the inside of the bladder with a camera.
"This data suggest that cystoscopy alone remains the most cost-effective strategy," said study author Dr. Jose Karam, a urologic oncology fellow at The University of Texas M.D. Anderson Cancer Center in Houston. "The addition of urine tests adds to the cost without detection of invasive disease, suggesting that we should be using these markers carefully and judiciously when surveying patients with bladder cancer."
Both Vogelzang and Sartor disclosed numerous ties with pharmaceutical companies.
The Genitourinary Cancers Symposium is sponsored jointly by the American Society for Clinical Oncology, the American Society for Radiation Oncology and the Society of Urologic Oncology.
There's more on genitourinary cancers at the U.S. National Cancer Institute.
SOURCES: March 3, 2010, teleconference with Nicholas J. Vogelzang, M.D., chair and medical director, developmental therapeutics committee, U.S. Oncology; Oliver Sartor, M.D., Piltz Professor for Cancer Research, Tulane Cancer Center, New Orleans; Jack Groskopf, Ph.D., director of research and development in cancer diagnostics, Gen-Probe Inc., San Diego; Christopher Jones, M.D., partner, Radiological Associates of Sacramento; and Jose Karam, M.D., urologic oncology fellow, The University of Texas M. D. Anderson Cancer C
All rights reserved